GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents
- Conditions
- Migraine Disorders
- Interventions
- Drug: Combination Tablet of Treximet (sumatriptan/naproxen sodium)
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 656
- Registration Number
- NCT00488514
- Locations
- πΊπΈ
GSK Investigational Site, Wenatchee, Washington, United States
GSK372475 Bioequivalence Study
- Conditions
- Healthy SubjectsDepressive Disorder
- First Posted Date
- 2007-06-19
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 66
- Registration Number
- NCT00488098
- Locations
- π¨π¦
GSK Investigational Site, Toronto, Ontario, Canada
Eltrombopag Taste Testing in Healthy Adult Volunteers
- Conditions
- Healthy SubjectsPurpura, Thrombocytopenic, Idiopathic
- First Posted Date
- 2007-06-19
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00487968
- Locations
- πΊπΈ
GSK Investigational Site, Overland Park, Kansas, United States
Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
- Conditions
- Neoplasms, Gastrointestinal Tract
- Interventions
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 273
- Registration Number
- NCT00486954
- Locations
- π¨π³
GSK Investigational Site, Tau-Yuan County, Taiwan
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: PlaceboBiological: HPV-16/18 VLP/AS04 vaccine (Cervarix TM)
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2018-07-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 225
- Registration Number
- NCT00485732
- Locations
- π°π·
GSK Investigational Site, Seoul, Korea, Republic of
REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study
- Conditions
- Parkinson DiseaseParkinson's Disease
- Interventions
- Drug: ROPDrug: ROP+L-Dopa
- First Posted Date
- 2007-06-12
- Last Posted Date
- 2010-12-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 123
- Registration Number
- NCT00485069
- Locations
- π―π΅
GSK Investigational Site, Tokyo, Japan
A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function
- First Posted Date
- 2007-06-07
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 59
- Registration Number
- NCT00483860
- Locations
- π³π±
GSK Investigational Site, Utrecht, Netherlands
Oral Contraceptive Interaction Study for GW273225
- Conditions
- Bipolar Disorder
- Interventions
- Drug: GW273225Drug: COC
- First Posted Date
- 2007-06-07
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00483535
- Locations
- π¬π§
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
Examine the Effect of Repeat Inhaled Doses of GW870086X on Lung Function in Mild Asthmatic Male Subjects
- Conditions
- Asthma
- Interventions
- Drug: GW870086XDrug: Placebo
- First Posted Date
- 2007-06-07
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT00483899
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.
- Conditions
- Human Papillomavirus (HPV) Infection
- Interventions
- Biological: CervarixDrug: Placebo Al(OH)3
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 676
- Registration Number
- NCT00481767
- Locations
- πΉπΏ
GSK Investigational Site, Mwanza, Tanzania